April 1, 2025 06:52 AM EDTUpdated 03:23 PM

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Ayisha Sharma

News Reporter

Eli Lilly’s RNA candidate has reduced levels of a protein linked with cardiovascular disease risk in a mid-stage trial in patients with high cholesterol. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche CEO warns that tariffs could impact dealmaking

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

Bristol Myers' transition moves forward as it raises 2025 revenue forecast

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Lil­ly claims Phase 2 win for siR­NA ap­proach to mixed dys­lipi­demia

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia